Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocort...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
13 September 2012
|
| In: |
BMC endocrine disorders
Year: 2012, Volume: 12 |
| ISSN: | 1472-6823 |
| DOI: | 10.1186/1472-6823-12-19 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/1472-6823-12-19 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/1472-6823-12-19 
|
| Author Notes: | Andreas Tomaschitz, Astrid Fahrleitner-Pammer, Burkert Pieske, Nicolas Verheyen, Karin Amrein, Eberhard Ritz, Katharina Kienreich, Jörg H. Horina, Albrecht Schmidt, Elisabeth Kraigher-Krainer, Caterina Colantonio, Andreas Meinitzer and Stefan Pilz |
| Summary: | Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocorticoid receptor-blocker eplerenone to reduce parathyroid hormone secretion in patients with parathyroid hormone excess. |
|---|---|
| Item Description: | Gesehen am 11.07.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1472-6823 |
| DOI: | 10.1186/1472-6823-12-19 |